PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101
October 31, 2023 08:00 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological...
PaxMedica Announces 1-for-17 Reverse Stock Split
October 30, 2023 11:30 ET
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug...
PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
October 26, 2023 13:51 ET
|
PaxMedica, Inc.
TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited to announce that the Annals of General...
The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)
October 18, 2023 10:10 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Oct. 18, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce...
PaxMedica Appoints David Hough M.D. as Chief Medical Officer
August 16, 2023 08:30 ET
|
PaxMedica, Inc.
Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical...
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update
August 09, 2023 16:15 ET
|
PaxMedica, Inc.
TARRYTOWN, NY, Aug. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic...
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
July 24, 2023 08:00 ET
|
PaxMedica, Inc.
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful resultsThese results pave the way for filing an NDA for the use of PAX-101 (intravenous...
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
July 06, 2023 08:00 ET
|
PaxMedica, Inc.
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...
PaxMedica CEO Interviewed by The BRAIN Foundation
June 20, 2023 08:30 ET
|
PaxMedica, Inc.
Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on...
PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
June 08, 2023 08:00 ET
|
PaxMedica, Inc.
Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica’s Proprietary Pipeline Candidates TARRYTOWN, NY, June ...